BioSpace News Archive

Sporos Bioventures, LLC today announced the appointment of Rachel Humphrey, M.D. to its Board of Directors.

Alnylam Pharmaceuticals, Inc. today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 10 – 13, 2022.

Apexigen, Inc. today announced the appointment of Francis Sarena as Chief Operating Officer.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate at the following upcoming investor conferences in January.

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that it has successfully completed Part A of the previously announced clinical study PF614-102, “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics (PK) and Safety of Multiple-Ascending Oral Doses (MAD) of PF614 and the Food Effect and Bioavailability/Bioequivalence (BE) of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.”

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.

Applied Genetic Technologies Corporation announced that Sue Washer, President & Chief Executive Officer, and Susan Schneider M.D., Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright Virtual BioConnect Conference held January 10 – 13, 2022.

Yumanity Therapeutics announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.